Jennifer Patnaik
Concepts (389)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cataract | 18 | 2024 | 208 | 4.110 |
Why?
| Visual Acuity | 23 | 2025 | 321 | 3.870 |
Why?
| Macular Degeneration | 13 | 2023 | 159 | 2.980 |
Why?
| Geographic Atrophy | 10 | 2025 | 69 | 2.770 |
Why?
| Phacoemulsification | 13 | 2025 | 115 | 2.530 |
Why?
| Diabetic Retinopathy | 12 | 2024 | 177 | 2.080 |
Why?
| Wet Macular Degeneration | 6 | 2025 | 46 | 2.070 |
Why?
| Lenses, Intraocular | 6 | 2022 | 43 | 1.960 |
Why?
| Ophthalmology | 6 | 2025 | 82 | 1.590 |
Why?
| Cataract Extraction | 10 | 2024 | 97 | 1.490 |
Why?
| Intraocular Pressure | 10 | 2025 | 297 | 1.480 |
Why?
| Registries | 8 | 2025 | 1895 | 1.270 |
Why?
| Keratomileusis, Laser In Situ | 3 | 2024 | 22 | 1.160 |
Why?
| Glaucoma | 7 | 2025 | 219 | 1.060 |
Why?
| Retinal Detachment | 6 | 2023 | 56 | 1.040 |
Why?
| Photorefractive Keratectomy | 2 | 2024 | 19 | 1.010 |
Why?
| Retinopathy of Prematurity | 3 | 2022 | 141 | 1.000 |
Why?
| Myopia | 7 | 2024 | 47 | 0.980 |
Why?
| Keratotomy, Radial | 2 | 2022 | 9 | 0.970 |
Why?
| Optometrists | 1 | 2025 | 4 | 0.960 |
Why?
| Optometry | 1 | 2025 | 6 | 0.960 |
Why?
| Retrospective Studies | 48 | 2025 | 14461 | 0.840 |
Why?
| Refraction, Ocular | 6 | 2024 | 36 | 0.830 |
Why?
| Fluorescein Angiography | 7 | 2025 | 143 | 0.820 |
Why?
| Intraoperative Complications | 6 | 2024 | 129 | 0.790 |
Why?
| Capsule Opacification | 2 | 2021 | 22 | 0.770 |
Why?
| Tomography, Optical Coherence | 7 | 2025 | 186 | 0.770 |
Why?
| Eye Diseases | 2 | 2020 | 81 | 0.760 |
Why?
| Presbyopia | 1 | 2022 | 14 | 0.750 |
Why?
| Retinal Drusen | 4 | 2024 | 31 | 0.750 |
Why?
| Posterior Capsulotomy | 1 | 2021 | 7 | 0.740 |
Why?
| Burnout, Professional | 2 | 2025 | 404 | 0.740 |
Why?
| Humans | 107 | 2025 | 129271 | 0.740 |
Why?
| Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.740 |
Why?
| Trabeculectomy | 5 | 2025 | 71 | 0.730 |
Why?
| Lasers, Solid-State | 1 | 2021 | 22 | 0.730 |
Why?
| Follow-Up Studies | 18 | 2025 | 4887 | 0.720 |
Why?
| National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.720 |
Why?
| Aged, 80 and over | 23 | 2025 | 7055 | 0.700 |
Why?
| Automobile Driving | 2 | 2022 | 140 | 0.690 |
Why?
| Aged | 41 | 2025 | 22032 | 0.680 |
Why?
| Dementia | 1 | 2023 | 225 | 0.680 |
Why?
| Glaucoma, Open-Angle | 4 | 2023 | 101 | 0.660 |
Why?
| Colorado | 21 | 2025 | 4406 | 0.650 |
Why?
| Retinal Neovascularization | 1 | 2019 | 25 | 0.650 |
Why?
| Laser Therapy | 1 | 2021 | 131 | 0.650 |
Why?
| Postoperative Complications | 6 | 2024 | 2473 | 0.640 |
Why?
| Vitrectomy | 6 | 2025 | 64 | 0.630 |
Why?
| Estrogen Replacement Therapy | 1 | 2019 | 137 | 0.610 |
Why?
| Lens, Crystalline | 1 | 2020 | 122 | 0.600 |
Why?
| Female | 61 | 2025 | 68556 | 0.590 |
Why?
| Surveys and Questionnaires | 10 | 2025 | 5384 | 0.580 |
Why?
| Lasers, Excimer | 3 | 2024 | 29 | 0.580 |
Why?
| Strabismus | 3 | 2023 | 28 | 0.570 |
Why?
| Metformin | 1 | 2021 | 315 | 0.560 |
Why?
| West Nile Fever | 3 | 2011 | 49 | 0.540 |
Why?
| Internal Medicine | 1 | 2019 | 241 | 0.540 |
Why?
| Uveitis | 3 | 2022 | 127 | 0.540 |
Why?
| Emergency Medicine | 1 | 2019 | 215 | 0.530 |
Why?
| Male | 54 | 2025 | 63517 | 0.510 |
Why?
| Prevalence | 7 | 2025 | 2554 | 0.500 |
Why?
| Self Report | 2 | 2022 | 795 | 0.480 |
Why?
| Family Practice | 1 | 2019 | 455 | 0.480 |
Why?
| Breast Neoplasms | 3 | 2011 | 2140 | 0.470 |
Why?
| Middle Aged | 30 | 2025 | 31091 | 0.450 |
Why?
| Lens Implantation, Intraocular | 5 | 2022 | 59 | 0.440 |
Why?
| Internet | 4 | 2023 | 615 | 0.440 |
Why?
| Multimodal Imaging | 2 | 2025 | 110 | 0.430 |
Why?
| Diabetes Mellitus | 5 | 2024 | 1000 | 0.420 |
Why?
| Commerce | 2 | 2013 | 67 | 0.420 |
Why?
| Vitreous Body | 4 | 2022 | 109 | 0.410 |
Why?
| Fluocinolone Acetonide | 2 | 2023 | 19 | 0.400 |
Why?
| Ophthalmologic Surgical Procedures | 2 | 2025 | 57 | 0.400 |
Why?
| Smoking Prevention | 1 | 2013 | 163 | 0.390 |
Why?
| Tobacco Products | 1 | 2013 | 110 | 0.390 |
Why?
| Macula Lutea | 2 | 2023 | 21 | 0.380 |
Why?
| Risk Factors | 13 | 2024 | 9746 | 0.370 |
Why?
| Retinal Diseases | 2 | 2023 | 86 | 0.360 |
Why?
| Disease Notification | 2 | 2011 | 13 | 0.360 |
Why?
| United States | 16 | 2025 | 13828 | 0.360 |
Why?
| Lens Capsule, Crystalline | 2 | 2021 | 11 | 0.350 |
Why?
| Angiogenesis Inhibitors | 2 | 2023 | 220 | 0.340 |
Why?
| Biomarkers | 8 | 2025 | 3968 | 0.330 |
Why?
| Complement Factor B | 2 | 2022 | 108 | 0.330 |
Why?
| Comorbidity | 2 | 2011 | 1544 | 0.320 |
Why?
| Eye Injuries | 2 | 2021 | 46 | 0.320 |
Why?
| Cross-Sectional Studies | 8 | 2024 | 5051 | 0.310 |
Why?
| Complement System Proteins | 3 | 2022 | 317 | 0.310 |
Why?
| Diabetes Mellitus, Type 2 | 4 | 2023 | 2439 | 0.310 |
Why?
| Complement Activation | 3 | 2022 | 381 | 0.300 |
Why?
| Bangladesh | 3 | 2022 | 42 | 0.280 |
Why?
| Hepatitis A | 2 | 2011 | 25 | 0.280 |
Why?
| West Nile virus | 1 | 2007 | 38 | 0.280 |
Why?
| Health Promotion | 1 | 2013 | 719 | 0.270 |
Why?
| Refractive Errors | 2 | 2024 | 18 | 0.270 |
Why?
| Treatment Outcome | 9 | 2025 | 10202 | 0.270 |
Why?
| Local Government | 1 | 2006 | 28 | 0.260 |
Why?
| Choroid | 2 | 2024 | 62 | 0.260 |
Why?
| Vision Disorders | 3 | 2022 | 135 | 0.260 |
Why?
| Tonometry, Ocular | 2 | 2024 | 88 | 0.260 |
Why?
| Restaurants | 1 | 2006 | 20 | 0.260 |
Why?
| Chronic Disease | 2 | 2011 | 1716 | 0.250 |
Why?
| Public Health Administration | 1 | 2006 | 75 | 0.250 |
Why?
| Time Factors | 6 | 2025 | 6543 | 0.250 |
Why?
| Chemokine CCL5 | 2 | 2023 | 43 | 0.240 |
Why?
| Prospective Studies | 6 | 2025 | 7123 | 0.240 |
Why?
| Quality of Life | 5 | 2023 | 2687 | 0.240 |
Why?
| Surgery, Plastic | 1 | 2025 | 33 | 0.240 |
Why?
| Pilocarpine | 1 | 2025 | 15 | 0.240 |
Why?
| Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.230 |
Why?
| Education, Distance | 1 | 2025 | 43 | 0.230 |
Why?
| Glucocorticoids | 3 | 2024 | 578 | 0.230 |
Why?
| Cornea | 2 | 2022 | 128 | 0.230 |
Why?
| Retinoblastoma | 1 | 2024 | 31 | 0.230 |
Why?
| Infant | 10 | 2025 | 8975 | 0.230 |
Why?
| Gestational Age | 3 | 2022 | 874 | 0.220 |
Why?
| Birth Weight | 3 | 2022 | 505 | 0.220 |
Why?
| Aberrometry | 2 | 2021 | 9 | 0.220 |
Why?
| Telemedicine | 2 | 2024 | 789 | 0.220 |
Why?
| Optics and Photonics | 2 | 2021 | 41 | 0.220 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2023 | 530 | 0.210 |
Why?
| Macular Edema | 1 | 2023 | 43 | 0.210 |
Why?
| Homosexuality, Male | 2 | 2020 | 176 | 0.210 |
Why?
| Postoperative Period | 5 | 2025 | 329 | 0.210 |
Why?
| Cohort Studies | 6 | 2022 | 5409 | 0.200 |
Why?
| Eye Burns | 1 | 2022 | 12 | 0.200 |
Why?
| Insulins | 1 | 2023 | 37 | 0.200 |
Why?
| Vision, Low | 1 | 2022 | 16 | 0.200 |
Why?
| Compartment Syndromes | 1 | 2022 | 22 | 0.200 |
Why?
| Eyelid Diseases | 1 | 2022 | 18 | 0.200 |
Why?
| Outpatient Clinics, Hospital | 1 | 2023 | 81 | 0.200 |
Why?
| Incidence | 5 | 2022 | 2636 | 0.200 |
Why?
| Eyeglasses | 1 | 2022 | 5 | 0.190 |
Why?
| Odds Ratio | 4 | 2019 | 1019 | 0.190 |
Why?
| Scleritis | 1 | 2022 | 19 | 0.190 |
Why?
| Retinal Perforations | 1 | 2022 | 13 | 0.190 |
Why?
| Corneal Ulcer | 1 | 2022 | 16 | 0.190 |
Why?
| Clothing | 1 | 2022 | 19 | 0.190 |
Why?
| Ocular Hypertension | 1 | 2022 | 66 | 0.190 |
Why?
| Disease Progression | 3 | 2025 | 2630 | 0.180 |
Why?
| Adult | 19 | 2025 | 35497 | 0.180 |
Why?
| Weapons | 1 | 2021 | 8 | 0.180 |
Why?
| Civil Disorders | 1 | 2021 | 7 | 0.180 |
Why?
| Refractive Surgical Procedures | 1 | 2021 | 5 | 0.180 |
Why?
| Neonatal Screening | 1 | 2022 | 163 | 0.180 |
Why?
| Perception | 2 | 2021 | 337 | 0.180 |
Why?
| Artificial Intelligence | 1 | 2024 | 246 | 0.180 |
Why?
| Political Activism | 1 | 2021 | 9 | 0.180 |
Why?
| Eye Banks | 1 | 2020 | 6 | 0.180 |
Why?
| Sickness Impact Profile | 1 | 2020 | 55 | 0.180 |
Why?
| Corneal Transplantation | 1 | 2020 | 13 | 0.180 |
Why?
| Glycation End Products, Advanced | 1 | 2021 | 76 | 0.180 |
Why?
| Glaucoma Drainage Implants | 1 | 2021 | 46 | 0.170 |
Why?
| Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| Accidents, Traffic | 1 | 2022 | 184 | 0.170 |
Why?
| SEER Program | 2 | 2011 | 202 | 0.170 |
Why?
| Neurodegenerative Diseases | 1 | 2022 | 112 | 0.170 |
Why?
| Feasibility Studies | 1 | 2024 | 867 | 0.170 |
Why?
| Oculomotor Muscles | 1 | 2020 | 38 | 0.170 |
Why?
| Health Status Disparities | 1 | 2023 | 251 | 0.170 |
Why?
| Language | 1 | 2023 | 283 | 0.170 |
Why?
| Scleral Buckling | 1 | 2019 | 18 | 0.160 |
Why?
| Retinal Hemorrhage | 1 | 2019 | 19 | 0.160 |
Why?
| Infant, Newborn | 5 | 2022 | 5736 | 0.160 |
Why?
| Hepatitis C | 1 | 2022 | 238 | 0.160 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2019 | 12 | 0.160 |
Why?
| Legislation, Drug | 1 | 2020 | 77 | 0.160 |
Why?
| Risk Assessment | 3 | 2019 | 3233 | 0.160 |
Why?
| Protective Factors | 1 | 2019 | 91 | 0.160 |
Why?
| Head Injuries, Closed | 1 | 2019 | 49 | 0.160 |
Why?
| MAP Kinase Kinase 1 | 1 | 2019 | 76 | 0.160 |
Why?
| Accreditation | 1 | 2019 | 80 | 0.160 |
Why?
| Specialization | 1 | 2020 | 144 | 0.160 |
Why?
| Complement Membrane Attack Complex | 1 | 2019 | 37 | 0.160 |
Why?
| Complement C3a | 1 | 2019 | 41 | 0.160 |
Why?
| Uveitis, Posterior | 1 | 2019 | 12 | 0.160 |
Why?
| Cardiovascular Diseases | 1 | 2011 | 2003 | 0.160 |
Why?
| Refugees | 1 | 2020 | 66 | 0.160 |
Why?
| Curriculum | 1 | 2025 | 910 | 0.150 |
Why?
| Choroidal Neovascularization | 1 | 2019 | 55 | 0.150 |
Why?
| Patient Care | 1 | 2019 | 108 | 0.150 |
Why?
| Case-Control Studies | 3 | 2022 | 3377 | 0.150 |
Why?
| Infant, Premature | 1 | 2022 | 541 | 0.150 |
Why?
| Medical Marijuana | 1 | 2020 | 111 | 0.150 |
Why?
| Child | 9 | 2025 | 20785 | 0.150 |
Why?
| Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.150 |
Why?
| Health Services Needs and Demand | 1 | 2020 | 263 | 0.150 |
Why?
| Sexually Transmitted Diseases | 3 | 2004 | 150 | 0.140 |
Why?
| Trabecular Meshwork | 1 | 2018 | 79 | 0.140 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 209 | 0.140 |
Why?
| Marijuana Use | 1 | 2020 | 192 | 0.130 |
Why?
| Marijuana Smoking | 1 | 2020 | 247 | 0.130 |
Why?
| Clinical Competence | 2 | 2025 | 1016 | 0.130 |
Why?
| Healthcare Disparities | 1 | 2023 | 575 | 0.130 |
Why?
| Mass Screening | 1 | 2024 | 1149 | 0.130 |
Why?
| Young Adult | 5 | 2025 | 12392 | 0.130 |
Why?
| Logistic Models | 2 | 2019 | 1985 | 0.120 |
Why?
| Population Surveillance | 2 | 2011 | 438 | 0.120 |
Why?
| Recovery of Function | 1 | 2019 | 641 | 0.120 |
Why?
| Disease Management | 1 | 2019 | 588 | 0.120 |
Why?
| Inflammation | 3 | 2023 | 2737 | 0.120 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 438 | 0.120 |
Why?
| Proportional Hazards Models | 2 | 2024 | 1197 | 0.120 |
Why?
| Fundus Oculi | 2 | 2025 | 61 | 0.110 |
Why?
| Disease Outbreaks | 2 | 2008 | 349 | 0.110 |
Why?
| Condoms | 2 | 2004 | 103 | 0.110 |
Why?
| Physicians | 1 | 2022 | 859 | 0.110 |
Why?
| Research Design | 1 | 2019 | 1043 | 0.100 |
Why?
| Medicare | 2 | 2024 | 706 | 0.100 |
Why?
| Hypoglycemic Agents | 1 | 2021 | 1219 | 0.100 |
Why?
| Melanoma | 1 | 2019 | 729 | 0.100 |
Why?
| Sexual Behavior | 4 | 2004 | 481 | 0.100 |
Why?
| Skin Neoplasms | 1 | 2019 | 824 | 0.100 |
Why?
| Axial Length, Eye | 2 | 2024 | 15 | 0.090 |
Why?
| Child, Preschool | 6 | 2025 | 10459 | 0.090 |
Why?
| Tertiary Healthcare | 2 | 2022 | 29 | 0.090 |
Why?
| Immunologic Factors | 2 | 2024 | 230 | 0.090 |
Why?
| Adolescent | 7 | 2025 | 20315 | 0.090 |
Why?
| Diagnostic Errors | 1 | 2011 | 162 | 0.090 |
Why?
| Shellfish Poisoning | 1 | 2009 | 1 | 0.080 |
Why?
| Vibrio Infections | 1 | 2009 | 2 | 0.080 |
Why?
| Primary Prevention | 1 | 2011 | 188 | 0.080 |
Why?
| Shellfish | 1 | 2009 | 6 | 0.080 |
Why?
| Food Industry | 1 | 2009 | 15 | 0.080 |
Why?
| Internship and Residency | 1 | 2019 | 1047 | 0.080 |
Why?
| Food Microbiology | 1 | 2009 | 61 | 0.080 |
Why?
| Cause of Death | 1 | 2011 | 392 | 0.080 |
Why?
| Mortality | 1 | 2011 | 307 | 0.080 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 851 | 0.080 |
Why?
| Academic Medical Centers | 2 | 2022 | 474 | 0.070 |
Why?
| Antineoplastic Agents | 1 | 2019 | 2054 | 0.070 |
Why?
| Cryptosporidiosis | 1 | 2008 | 21 | 0.070 |
Why?
| Anti-Inflammatory Agents | 2 | 2022 | 480 | 0.070 |
Why?
| Disease Reservoirs | 1 | 2007 | 19 | 0.070 |
Why?
| Maternal-Child Health Centers | 1 | 2007 | 9 | 0.070 |
Why?
| Culicidae | 1 | 2007 | 30 | 0.070 |
Why?
| Sentinel Surveillance | 1 | 2007 | 41 | 0.070 |
Why?
| Health Services Administration | 1 | 2007 | 8 | 0.070 |
Why?
| Gastroenteritis | 1 | 2008 | 67 | 0.070 |
Why?
| Relief Work | 1 | 2007 | 19 | 0.070 |
Why?
| Horses | 1 | 2007 | 107 | 0.070 |
Why?
| Telephone | 1 | 2008 | 167 | 0.070 |
Why?
| Chickens | 1 | 2007 | 189 | 0.070 |
Why?
| Birds | 1 | 2007 | 86 | 0.070 |
Why?
| Geography | 1 | 2007 | 186 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 833 | 0.070 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2023 | 3628 | 0.060 |
Why?
| Health Care Surveys | 1 | 2008 | 557 | 0.060 |
Why?
| Predictive Value of Tests | 1 | 2011 | 1949 | 0.060 |
Why?
| Disasters | 1 | 2007 | 91 | 0.060 |
Why?
| Smoking | 1 | 2013 | 1499 | 0.060 |
Why?
| Databases, Factual | 1 | 2011 | 1266 | 0.060 |
Why?
| Immunoglobulins | 1 | 2006 | 160 | 0.060 |
Why?
| Environment | 1 | 2007 | 344 | 0.060 |
Why?
| Immunization Programs | 1 | 2007 | 214 | 0.060 |
Why?
| Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| Muscarinic Agonists | 1 | 2025 | 16 | 0.060 |
Why?
| Ganglionic Stimulants | 1 | 2005 | 12 | 0.060 |
Why?
| Lubricant Eye Drops | 1 | 2024 | 9 | 0.060 |
Why?
| Needs Assessment | 1 | 2007 | 359 | 0.060 |
Why?
| Rwanda | 1 | 2024 | 12 | 0.060 |
Why?
| Retinal Neoplasms | 1 | 2024 | 26 | 0.060 |
Why?
| Patient Discharge | 1 | 2011 | 835 | 0.060 |
Why?
| Conjunctivitis | 1 | 2024 | 30 | 0.060 |
Why?
| Ophthalmic Solutions | 1 | 2024 | 75 | 0.060 |
Why?
| Capacity Building | 1 | 2024 | 59 | 0.060 |
Why?
| Attitude to Health | 1 | 2007 | 430 | 0.050 |
Why?
| Vision Tests | 1 | 2023 | 16 | 0.050 |
Why?
| Hospitals, County | 1 | 2023 | 10 | 0.050 |
Why?
| Retinal Pigment Epithelium | 1 | 2024 | 70 | 0.050 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 983 | 0.050 |
Why?
| Postoperative Care | 1 | 2025 | 241 | 0.050 |
Why?
| Electronic Health Records | 1 | 2011 | 970 | 0.050 |
Why?
| Observational Studies as Topic | 1 | 2023 | 110 | 0.050 |
Why?
| Health Surveys | 2 | 2021 | 493 | 0.050 |
Why?
| Laser Coagulation | 1 | 2023 | 57 | 0.050 |
Why?
| Mentors | 1 | 2024 | 178 | 0.050 |
Why?
| Interleukin-4 | 1 | 2023 | 212 | 0.050 |
Why?
| Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| Gonorrhea | 1 | 2003 | 57 | 0.050 |
Why?
| Tobacco Use Disorder | 1 | 2005 | 236 | 0.050 |
Why?
| Orbit | 1 | 2022 | 57 | 0.050 |
Why?
| Nicotine | 1 | 2005 | 302 | 0.050 |
Why?
| Aqueous Humor | 1 | 2022 | 33 | 0.050 |
Why?
| Communication Barriers | 1 | 2023 | 98 | 0.050 |
Why?
| Phenotype | 2 | 2022 | 3074 | 0.050 |
Why?
| Cluster Analysis | 1 | 2023 | 479 | 0.050 |
Why?
| Drug Implants | 1 | 2022 | 82 | 0.050 |
Why?
| Alanine Transaminase | 1 | 2022 | 153 | 0.050 |
Why?
| Reference Standards | 1 | 2022 | 176 | 0.050 |
Why?
| Safety-net Providers | 1 | 2023 | 109 | 0.050 |
Why?
| Albumins | 1 | 2022 | 103 | 0.050 |
Why?
| Capsulorhexis | 1 | 2021 | 8 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 98 | 0.050 |
Why?
| Fibrinogen | 1 | 2022 | 163 | 0.050 |
Why?
| Morbidity | 1 | 2022 | 300 | 0.050 |
Why?
| Dissent and Disputes | 1 | 2021 | 17 | 0.040 |
Why?
| Intraoperative Period | 1 | 2020 | 53 | 0.040 |
Why?
| Hepacivirus | 1 | 2022 | 235 | 0.040 |
Why?
| Crowding | 1 | 2021 | 35 | 0.040 |
Why?
| Smoking Cessation | 1 | 2005 | 405 | 0.040 |
Why?
| Biometry | 1 | 2021 | 69 | 0.040 |
Why?
| Myotomy | 1 | 2020 | 11 | 0.040 |
Why?
| Vision, Binocular | 1 | 2020 | 17 | 0.040 |
Why?
| Myanmar | 1 | 2020 | 6 | 0.040 |
Why?
| Intravitreal Injections | 1 | 2020 | 56 | 0.040 |
Why?
| Risk-Taking | 1 | 2003 | 346 | 0.040 |
Why?
| Rupture | 1 | 2020 | 91 | 0.040 |
Why?
| Eye Movements | 1 | 2020 | 59 | 0.040 |
Why?
| Survival Rate | 1 | 2024 | 1869 | 0.040 |
Why?
| Health Education | 1 | 2003 | 334 | 0.040 |
Why?
| Adrenal Cortex Hormones | 1 | 2023 | 522 | 0.040 |
Why?
| Canada | 1 | 2020 | 350 | 0.040 |
Why?
| HIV | 1 | 2020 | 227 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2021 | 424 | 0.040 |
Why?
| Circadian Rhythm | 1 | 2023 | 413 | 0.040 |
Why?
| Remission, Spontaneous | 1 | 2019 | 37 | 0.040 |
Why?
| C-Reactive Protein | 1 | 2021 | 400 | 0.040 |
Why?
| Ambulatory Care | 1 | 2023 | 504 | 0.040 |
Why?
| Microscopy, Acoustic | 1 | 2018 | 8 | 0.040 |
Why?
| Attitude | 1 | 2021 | 252 | 0.040 |
Why?
| Pyrimidinones | 1 | 2019 | 103 | 0.040 |
Why?
| Preoperative Period | 1 | 2019 | 114 | 0.040 |
Why?
| Ophthalmoscopy | 1 | 2018 | 35 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2023 | 1004 | 0.040 |
Why?
| Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2021 | 523 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2019 | 645 | 0.040 |
Why?
| Prosthesis Design | 1 | 2020 | 306 | 0.040 |
Why?
| Longitudinal Studies | 1 | 2025 | 2716 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2020 | 569 | 0.040 |
Why?
| Physical Examination | 1 | 2019 | 234 | 0.030 |
Why?
| Ambulatory Care Facilities | 3 | 2004 | 226 | 0.030 |
Why?
| Referral and Consultation | 1 | 2022 | 727 | 0.030 |
Why?
| Stents | 1 | 2021 | 502 | 0.030 |
Why?
| Sleep | 1 | 2023 | 684 | 0.030 |
Why?
| Sex Characteristics | 1 | 2022 | 736 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2024 | 892 | 0.030 |
Why?
| Equipment Design | 1 | 2018 | 513 | 0.030 |
Why?
| Mental Health | 1 | 2022 | 685 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2023 | 3080 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2019 | 1497 | 0.030 |
Why?
| Anxiety | 1 | 2022 | 962 | 0.030 |
Why?
| Program Evaluation | 2 | 2011 | 872 | 0.030 |
Why?
| Proteins | 1 | 2020 | 941 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2024 | 1708 | 0.030 |
Why?
| Child Abuse | 1 | 2019 | 511 | 0.030 |
Why?
| Proteomics | 1 | 2020 | 1054 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2022 | 1933 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2019 | 890 | 0.030 |
Why?
| Depression | 1 | 2022 | 1306 | 0.030 |
Why?
| Pandemics | 1 | 2021 | 1482 | 0.020 |
Why?
| Animals | 3 | 2009 | 35309 | 0.020 |
Why?
| Blood Glucose | 1 | 2021 | 2097 | 0.020 |
Why?
| Prognosis | 1 | 2019 | 3773 | 0.020 |
Why?
| Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1556 | 0.020 |
Why?
| Whooping Cough | 1 | 2011 | 49 | 0.020 |
Why?
| Medical Audit | 1 | 2011 | 74 | 0.020 |
Why?
| Haemophilus Infections | 1 | 2011 | 39 | 0.020 |
Why?
| Hospitals, Urban | 1 | 2011 | 129 | 0.020 |
Why?
| International Classification of Diseases | 1 | 2011 | 122 | 0.020 |
Why?
| Cryptosporidium | 1 | 2008 | 13 | 0.020 |
Why?
| Caliciviridae Infections | 1 | 2008 | 17 | 0.020 |
Why?
| Norovirus | 1 | 2008 | 23 | 0.020 |
Why?
| Residence Characteristics | 1 | 2011 | 327 | 0.020 |
Why?
| Aid to Families with Dependent Children | 1 | 2007 | 4 | 0.020 |
Why?
| Faculty | 1 | 2008 | 137 | 0.020 |
Why?
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 92 | 0.020 |
Why?
| Family Characteristics | 1 | 2008 | 178 | 0.020 |
Why?
| Medically Uninsured | 1 | 2007 | 126 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 1839 | 0.020 |
Why?
| Guideline Adherence | 1 | 2009 | 526 | 0.010 |
Why?
| Pharmaceutical Preparations | 1 | 2007 | 171 | 0.010 |
Why?
| Maryland | 1 | 2005 | 46 | 0.010 |
Why?
| Administration, Topical | 1 | 2005 | 145 | 0.010 |
Why?
| Urban Health Services | 1 | 2004 | 61 | 0.010 |
Why?
| Acute Disease | 1 | 2007 | 978 | 0.010 |
Why?
| Patient Satisfaction | 1 | 2008 | 632 | 0.010 |
Why?
| Office Visits | 1 | 2003 | 84 | 0.010 |
Why?
| Syphilis | 1 | 2003 | 32 | 0.010 |
Why?
| Administration, Oral | 1 | 2005 | 785 | 0.010 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2003 | 267 | 0.010 |
Why?
| Risk | 1 | 2004 | 854 | 0.010 |
Why?
| Mothers | 1 | 2007 | 730 | 0.010 |
Why?
| Urban Population | 1 | 2004 | 441 | 0.010 |
Why?
| HIV Infections | 1 | 2003 | 2721 | 0.000 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|